Roche Bullish On Alzheimer’s Prospects
This article was originally published in The Pink Sheet Daily
Roche has reported a solid performance for the first half of 2015 and provided a promising, though data-light, R&D update. A number of Phase III starts and filing timelines have been confirmed, and the Swiss pharma also gave an update on its Alzheimer's ambitions.
You may also be interested in...
New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.
Roche plans to file I.V. anti-CD20 antibody ocrelizumab in multiple sclerosis early in 2016, after disclosing that the drug met endpoints in two Phase III studies against Merck Serono’s Rebif.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.